Open an account

Spruce Biosciences

SPRB · NASDAQ

$41.23+$0.83 (+2.05%)TodayMarket closed ·
Prev close $40.40

About SPRB

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2020-10-09. The company has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.

Employees
8
Headquarters
South San Francisco, California
Listed
Oct 9, 2020
Sector
Health Care
Industry
Biotechnology
Website
sprucebio.com

SPRB key statistics

Market cap
118.50M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
85.34K
Volume
52.64K
Open price
$40.57
High today
$42.65
Low today
$40.40
52 Week high
$154.95
52 Week low
$38.06

Spruce Biosciences (SPRB) at a glance

Spruce Biosciences (SPRB) last traded at $41.23, with a market cap of 118.50M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $40.40 and $42.65. The current price is 2.1% above the day's low and 3.3% below its high.

Volume so far is 52.64K shares, below the average of 85.34K shares a day.

Over the past year Spruce Biosciences has ranged from $38.06 to $154.95, and now sits 3% of the way up that range.

Spruce Biosciences met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$6.68 per share against an estimate of -$5.92.

The average analyst price target is $150.96, 266.1% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 9 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $150.96
Low
$105.04
Now
$41.23
High
$241.50

SPRB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 32.0% on average.

  1. Q3 FY24: reported -$15.75 per share against an estimate of -$18.17
  2. Q4 FY24: reported -$42.75 per share against an estimate of -$16.07
  3. Q1 FY25: reported -$24.00 per share against an estimate of -$16.42
  4. Q2 FY25: reported -$3.50 per share against an estimate of -$19.51
  5. Q3 FY25: reported -$14.58 per share against an estimate of -$14.21
  6. Q4 FY25: reported -$11.28 per share against an estimate of -$8.15
  7. Q1 FY26: reported -$8.94 per share against an estimate of -$8.99
  8. Q2 FY26: reported -$6.68 per share against an estimate of -$5.92

SPRB news

  • Press releaseBusiness Wire

    Spruce Biosciences to Participate in the Craig-Hallum Biotech Catalyst Conference

  • Press releaseBusiness Wire

    Spruce Biosciences Announces Presentation of MPS IIIB Natural History Data at the 55th Child Neurology Society Annual Meeting

  • Press releaseBusiness Wire

    Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releaseBusiness Wire

    Spruce Biosciences Announces Launch of MPS3BStudy.com

  • Press releaseBusiness Wire

    Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

  • Press releaseBusiness Wire

    Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

  • Press releaseBusiness Wire

    Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

  • Press releaseBusiness Wire

    Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

Similar companies

Companies in the same industry as Spruce Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.